7T MRI Seminar: What is the current evidence of the diagnostic value of 7T MRI?
Abstract
Evidence-based medicine is the paradigm for both individual medical decisions and global healthcare policies. 7T MRI has been available as a clinically approved diagnostic tool since 2017; it seems timely to ask what body of comparative evidence exists for 7T MRI. We assessed the evidence of the diagnostic comparative features of 7T MRI compared to the standard of care (3T, 1.5T MRI or other clinically used imaging modalities) with a systematic literature search and intended meta-analysis. We will discuss the body of comparative evidence for the use of 7T MRI and identifying evidence gaps to motivate further research.
Piotr Radojewski
Translational Imaging Center, SITEM-Insel, Bern, Switzerland
Dr. Piotr Radojewski is the Managing Director of the Translational Imaging Center at SITEM-Insel. He is Holder of an MD in human medicine and is engaged in both scientific and clinical work at the Institute for Diagnostic and Interventional Neuroradiology at Inselspital. His responsibilities include coordinating research projects and collaborating with industry, with a particular focus on ultra-high-field MRI. Dr. Radojewski brings extensive expertise at the intersection of clinical medicine, research, and industry. He is a graduate of an executive education program at Stanford Graduate School of Business and a design-thinking program at the Hasso Plattner Institute. He has experience advising companies on transitioning research projects into market-ready products and has acted as an early-stage investor.
Date and time
Wednesday, October 16th, 2024, 11:00 to 12:00 pm CEST
Location
Virtual on Zoom and on-site at Campus Biotech Room H8-01-F.
JOIN US!
If attending on-site, no registration is required.
Please join here via Zoom (Meeting ID: 654 0494 5981)